Immunovant’s (IMVT) Overweight Rating Reaffirmed at Cantor Fitzgerald

Immunovant (NASDAQ:IMVT – Get Free Report)‘s stock had its “overweight” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Wednesday, Benzinga reports. Several other equities analysts have also issued reports on the company. HC Wainwright restated a “buy” rating and set a $51.00 price target […]

Leave a Reply

Your email address will not be published.

Previous post Tigo Energy (NASDAQ:TYGO) Price Target Cut to $4.50
Next post SPDR S&P Semiconductor ETF (NYSEARCA:XSD) Sees Unusually-High Trading Volume